Divya Nagarajan
Overview
Explore the profile of Divya Nagarajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagarajan D, Parracho R, Corujo D, Xie M, Kutkaite G, Olsen T, et al.
J Clin Invest
. 2024 Sep;
134(21).
PMID: 39255035
Childhood neuroblastoma with MYCN amplification is classified as high risk and often relapses after intensive treatments. Immune checkpoint blockade therapy against the PD-1/L1 axis shows limited efficacy in patients with...
2.
McArdle S, Nagarajan D, Barish M
Front Immunol
. 2024 May;
15:1407930.
PMID: 38715607
No abstract available.
3.
Papakyriacou I, Kutkaite G, Rubies Bedos M, Nagarajan D, Alford L, Menden M, et al.
Nat Commun
. 2024 Apr;
15(1):3581.
PMID: 38678024
Immune checkpoint blockade therapy aims to activate the immune system to eliminate cancer cells. However, clinical benefits are only recorded in a subset of patients. Here, we leverage genome-wide CRISPR/Cas9...
4.
Vajjiravel P, Nagarajan D, Pugazhenthi V, Suresh A, Sivalingam M, Venkat A, et al.
Plant Physiol Biochem
. 2024 Jan;
207:108350.
PMID: 38199026
Salt stress is a recognized annihilating abiotic stress that has a significant impact on agricultural and horticulture crop productivity. Plant development faces three distinct dangers as a result of salt...
5.
Tunali G, Rubies Bedos M, Nagarajan D, Fridh P, Papakyriacou I, Mao Y
J Clin Invest
. 2023 Feb;
133(7).
PMID: 36757800
Inflammatory mediators released by cancer cells promote the induction of immune suppression and tolerance in myeloid cells. IL-1 receptor-associated kinase-3 (IRAK3) is a pseudokinase that inhibits IL-1/TLR signaling, but its...
6.
Alsinbili A, Nagarajan D
Future Healthc J
. 2022 Oct;
9(Suppl 2):56-57.
PMID: 36310994
No abstract available.
7.
Williams C, McEvoy C, Lim M, Shea S, Kumar V, Nagarajan D, et al.
Children (Basel)
. 2022 May;
9(5).
PMID: 35626925
Over 50,000 children are hospitalized annually for traumatic brain injury (TBI) and face long-term cognitive morbidity. Over 50% develop sleep/wake disturbances (SWDs) that can affect brain development and healing. We...
8.
Almshayakhchi R, Nagarajan D, Vadakekolathu J, Guinn B, Reeder S, Brentville V, et al.
Front Oncol
. 2021 Jul;
11:636977.
PMID: 34262856
Many cancers, including myeloid leukaemia express the cancer testis antigen (CTA) DDX43 (HAGE) and/or the oncogene Wilms' tumour (WT1). Here we demonstrate that HAGE/WT1-ImmunoBody vaccines derived T-cells can kill human...
9.
Nagarajan D, Pearson J, Brentville V, Metheringham R, Pockley A, Durrant L, et al.
Immunol Cell Biol
. 2021 Jun;
99(9):972-989.
PMID: 34105800
The management of patients with triple-negative breast cancer (TNBC) continues to pose a significant clinical challenge. Less than 30% of women with metastatic TNBC survive 5 years, despite adjuvant chemotherapy...
10.
Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley A, McArdle S
Front Immunol
. 2021 Mar;
11:615240.
PMID: 33679703
Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore...